Our therapeutic targets are mechanistically driven and supported by rigorous in vitro and in vivo safety and pharmacology models. New compounds are generated from internal lead optimization programs and quickly enter non-clinical screening, including toxicity, pharmacodynamics, and pharmacokinetics studies. Medicinal chemists, biologists, pharmacologists, and translational medicine experts collaborate closely to select drug candidates based on predefined criteria and develop their target product profile focusing on the therapeutic potential and differentiated advantages in each drug’s intended uses.